Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTR5A | P47898 | 4/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | MLNR | O43193 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3227878 | 0.99 | GAA (0.42) | GAAHTR5APDCD1CD274ROCK1 | |
| SCHEMBL4229640 | 0.97 | PDCD1 (0.39) | GAAHTR5APDCD1CD274ROCK1 | |
| SCHEMBL1496850 | 0.93 | GAA (0.41) | GAAHTR5APDCD1CD274ROCK1 | |
| SCHEMBL1497163 | 0.89 | GAA (0.36) | GAAHTR5APDCD1CD274ROCK1 | |
| SCHEMBL2476409 | 0.88 | HDAC1 (0.43) | GAAHTR5APPARGPPARDPPARA | |
| SCHEMBL1497154 | 0.88 | GAA (0.47) | GAAHTR5APDCD1CD274PPARG | |
| SCHEMBL4225113 | 0.87 | BRS3 (0.40) | HTR5APDCD1CD274ROCK1HDAC1 | |
| SCHEMBL3231989 | 0.86 | PDCD1 (0.40) | HTR5APDCD1CD274ROCK1HDAC1 | |
| SCHEMBL4224190 | 0.85 | HDAC1 (0.45) | GAAHTR5APDCD1CD274ROCK1 | |
| SCHEMBL13456917 | 0.85 | PDCD1 (0.40) | PDCD1CD274ROCK1HDAC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012972-B2 | Pyridinecarboxylic acid (2-aminophenyl) amide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8012972-B2 | Pyridinecarboxylic acid (2-aminophenyl) amide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20100063045-A1 | NOVEL PYRIDINECARBOXYLIC ACID (2-AMINOPHENYL) AMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063045-A1 | NOVEL PYRIDINECARBOXYLIC ACID (2-AMINOPHENYL) AMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2135620-A1 | OCULAR HYPOTENSIVE AGENT COMPRISING COMPOUND CAPABLE OF INHIBITING HISTONE DEACETYLASE AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-23 | — | — | EP | disclosed |
| EP-2133339-A1 | NOVEL (2-AMINOPHENYL)PYRIDINECARBOXAMIDE DERIVATIVE HAVING UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063045-A1 | NOVEL PYRIDINECARBOXYLIC ACID (2-AMINOPHENYL) AMIDE DERIVATIVE HAVING UREA STRUCTURE | HCAR1, CBR1, UACA | GAA 4429/4885HTR5A 3156/4885PDCD1 1397/4885 |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | HDAC1, HDAC9, HDAC5 | GAA 757/4885HTR5A 2403/4885PDCD1 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.